- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 12:11 | Bayer earns FDA untitled letter for Nubeqa's 'attention-grabbing visuals' | ||
| Mi | With Austedo at helm, Teva's impressive innovative drug sales signal company's successful metamorphosis | ||
| Mi | AstraZeneca CEO's conservative MFN model excludes reference markets from forecast | ||
| Mi | AbbVie outlines Skyrizi defense against new J&J plaque psoriasis rival Icotyde | ||
| Mi | Regeneron's quarterly sales of Eylea drop below $1B for the first time in 8 years | ||
| Mi | New GSK CEO's first quarter boosted by Shingrix surge as Exdensur stumbles in switch trial | ||
| Mi | Pfizer looks to jump start Elrexfio with topline win in second-line myeloma | ||
| Mi | Chiesi lays out $1.9B to bolster rare disease offerings with KalVista buyout | ||
| Mi | AstraZeneca restarts $300M investment in UK, but Merck not budging | ||
| Di | Novartis CEO calls for 'complete rethink' of Europe's drug pricing policies | ||
| Di | Pfizer's victory in delaying Vyndamax generics is mixed bag for BridgeBio: analysts | ||
| Di | FDA flags concerns for AstraZeneca's camizestrant, Truqap ahead of advisory committee meeting | ||
| Di | FDA turns up heat on Amgen, proposing to rescind approval of Tavneos | ||
| Di | Rocket sells priority review voucher for $180M after Kresladi gene therapy approval | ||
| Di | AstraZeneca's Breztri nabs FDA asthma nod, adding fuel to blockbuster launch | ||
| Di | Haleon scores branding goal with star-studded soccer offensive | ||
| Di | Novartis stands by $5B Pluvicto goal despite European regulatory setback, bispecific competition | ||
| Mo | Mundipharma, CorMedix eye antifungal expansion after Rezzayo trial win | ||
| Mo | Astellas counts on new medicines to offset projected Xtandi decline in fiscal 2026 | ||
| Mo | Pfizer settles with 2 generic Vyndamax makers in latest twist to ATTR market: analysts | ||
| Mo | Haleon nabs Google exec Richard Manso as US chief marketing officer | ||
| Mo | Sun Pharma strikes biopharma's largest deal of '26 with $11.75B buyout of Organon | ||
| Mo | Ligand snaps up fellow biotech royalty aggregator Xoma for $739M | ||
| Fr | FDA snubs AbbVie's prospective Botox heir amid series of manufacturing-related CRLs | ||
| Fr | Sanofi gains long-awaited win for tolebrutinib as EU regulator endorses MS drug for approval |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.